Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.

@article{Hoffmann2007NatureAP,
  title={Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.},
  author={Bjoern Hoffmann and Michael Beck and Gere Sunder-Plassmann and Walter Borsini and R. Frank Ricci and Atul Mehta},
  journal={The Clinical journal of pain},
  year={2007},
  volume={23 6},
  pages={535-42}
}
BACKGROUND Fabry disease is a multisystemic life-threatening lysosomal storage disorder caused by deficiency of alpha-galactosidase A. Symptoms of the disease may occur in different organs including kidney, heart, and the nervous system. OBJECTIVES To evaluate the nature and prevalence of pain in a large cohort of patients with Fabry disease and to assess the effect of enzyme replacement therapy (ERT) with agalsidase alfa. METHODS Retrospective analysis of the data of 752 patients with… CONTINUE READING